Glypressin

Glypressin is a prescription medication that contains the active ingredient terlipressin acetate. It is supplied as an intravenous preparation, although the specific strength is not disclosed in the available product information. Glypressin belongs to the vasopressin analog class and acts as a selective V1‑receptor agonist. It is marketed in the European Union for use as a hemodynamic agent in specific clinical situations and therapeutic applications.

Glypressin is indicated for the management of acute bleeding from esophageal varices and may be employed in certain off‑label situations such as hepatorenal syndrome.

- Control of acute variceal hemorrhage in patients with portal hypertension. - Adjunctive therapy to endoscopic treatment of bleeding esophageal or gastric varices. - Support of systemic vascular resistance in selected cases of septic shock (off‑label). - Management of hepatorenal syndrome in patients with advanced liver disease (off‑label). - Temporary reduction of portal venous pressure during diagnostic or therapeutic procedures.

The safety profile of Glypressin reflects its vasoconstrictive activity, with most patients experiencing mild, transient reactions while a smaller proportion may develop serious complications.

Common: - Headache - Nausea or vomiting - Abdominal discomfort - Flushing or warmth at the infusion site - Transient hypertension

Serious: - Myocardial ischemia or infarction - Severe hypertension with risk of stroke - Cardiac arrhythmias - Peripheral ischemia leading to tissue necrosis - Acute renal failure

Before initiating Glypressin, clinicians should evaluate patient history and monitor specific parameters to minimize risk.

- Known hypersensitivity to terlipressin or vasopressin analogs. - Pre‑existing cardiovascular disease, especially coronary artery disease. - Uncontrolled hypertension or severe aortic stenosis. - Active myocardial ischemia or recent myocardial infarction. - Pregnancy and lactation status, as safety data are limited. - Renal impairment requiring close monitoring of urine output. - Concomitant use of vasoconstrictive agents that may amplify blood pressure effects.

Glypressin can interact with other drugs that influence vascular tone, cardiac function, or renal perfusion.

Avoid: - Other vasopressors (e.g., norepinephrine, phenylephrine) that may cause excessive vasoconstriction. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil) due to risk of severe hypotension on reversal. - Ergot alkaloids, which can potentiate peripheral ischemia.

Use with caution: - Beta‑blockers, which may mask tachycardia. - Diuretics, especially loop diuretics, that affect intravascular volume. - Anticoagulants, as reduced portal pressure may alter bleeding risk. - Calcium channel blockers, which can influence systemic vascular resistance.